Valneva Races to Restructure as Shares Tumble and Pfizer Prepares Lyme Vaccine Filing
03.06.2026 - 15:34:12 | boerse-global.de
Valneva’s stock is heading into a packed June conference season nursing heavy losses, even as the company’s most important pipeline candidate — a Lyme disease vaccine developed with Pfizer — nears the regulatory finish line. The Paris-listed shares closed at €2.37 on Wednesday, down 2% on the day and 13% over the past week, pushing the relative strength index to 82.5, a classic overbought signal that underscores just how far the equity has fallen. At current levels, the stock sits 37% below its 200-day moving average and well under the 50-day line of €2.57.
The disconnect between pipeline promise and market sentiment is stark. Pfizer recently reported topline Phase 3 data for LB6V, formerly VLA15, showing more than 70% efficacy in individuals aged five and older, with no safety concerns. The partner is now preparing submissions to regulators, and Valneva bills LB6V as the world’s leading borreliosis vaccine candidate. That milestone alone would typically buoy a biotech stock, but the market’s focus has shifted to a deteriorating travel vaccine business.
Valneva slashed its full-year product revenue guidance to a range of €135 million to €150 million, down by €10 million from each end of the previous span. Total revenue is now expected to land between €145 million and €160 million. The culprit: geopolitical factors that have dampened demand for travel vaccines in key markets. The first-quarter numbers already told the story. Product sales fell to €30.5 million from €48.6 million a year earlier, dragged down by the planned wind-down of third-party product sales and shifting deliveries to the U.S. Department of Defense.
Should investors sell immediately? Or is it worth buying Valneva?
Management is responding with a restructuring plan that goes beyond cost-cutting. The workforce will be trimmed by 10% to 15% globally, and operating expenses are targeted to shrink by 25% to 35% this year compared with 2025. Those measures helped narrow operating cash burn from €8.1 million to just €0.3 million in the first quarter, though the net loss ballooned to €32.1 million from €9.2 million, largely due to restructuring charges. Cash and equivalents stood at €105.3 million at the end of March, topped up by €37 million from a capital increase in April.
Against that backdrop, Valneva is taking its message directly to doctors and investors. The company is a gold sponsor of the 10th Northern European Conference on Travel Medicine in Belfast from June 3 to 5, hosting a symposium on mosquito-borne diseases and vaccination strategies. The conference draws 500 to 1,000 healthcare professionals — precisely the audience that decides which shots to recommend. Separately, the management team will fan out to the Jefferies Global Healthcare Conference in New York, the Oddo BHF Nextcap Forum, and BNP Paribas’s SMID-Cap Conference in Paris.
The dual-track strategy — nurturing the existing travel vaccine franchise while banking on LB6V’s approval and commercial launch — is the backbone of Valneva’s turnaround narrative. The company is targeting sustainable profitability from 2027, contingent on a successful rollout with Pfizer. In the short term, though, the market is watching whether the June roadshows can rebuild confidence in a stock that has lost more than a third of its value from its 200-day average — and whether the Lyme vaccine’s regulatory filing can finally shift the narrative from cost-cutting to growth.
Ad
Valneva Stock: New Analysis - 3 June
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
